Last updated: October 30, 2026
SUSVIMO is Roche’s implant-based ranibizumab product for retinal disease. Its commercial proposition is reduced injection frequency, with refill exchanges generally scheduled every 24 weeks. FDA approval covers neovascular age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Commercial adoption has been constrained by a 2022 recall, procedural complexity, competition from Roche’s VABYSMO and Regeneron’s EYLEA HD, and the need for ophthalmologists to adopt an implant-based treatment workflow.
Roche does not separately disclose SUSVIMO revenue in its public product-sales tables. The company’s financial reporting groups smaller products or reports them without a detailed product-level figure. Publicly available financial evidence supports a conclusion of limited commercial contribution through 2024, while VABYSMO has become Roche’s principal growth driver in retinal disease.
What is SUSVIMO and how does the Port Delivery System work?
SUSVIMO combines ranibizumab with a surgically implanted ocular reservoir called the Port Delivery System, or PDS. The implant is placed in the eye and refilled through the sclera using a dedicated refill needle. The initial implant contains 100 mg/mL ranibizumab solution, with the implant delivering drug over an extended period.
The FDA-approved dosing interval is generally 24 weeks for the approved indications, subject to clinical assessment and label requirements. SUSVIMO is administered by ophthalmologists trained in the implantation and refill procedures. The product is not a conventional prefilled syringe or vial-based intravitreal injection.
The value proposition is operational rather than pharmacological:
| Attribute |
SUSVIMO |
Standard intravitreal anti-VEGF injection |
| Active ingredient |
Ranibizumab |
Often aflibercept, faricimab, ranibizumab, or bevacizumab |
| Delivery system |
Surgically implanted ocular reservoir |
Direct intravitreal injection |
| Typical maintenance interval |
Approximately 24 weeks under label protocols |
Often 4 to 16 weeks, depending on product and regimen |
| Procedure burden |
Implant surgery and refill procedures |
Repeated office injections |
| Primary commercial advantage |
Fewer treatment administrations |
Simpler workflow and broad physician familiarity |
| Main adoption barrier |
Surgery, refill training, and device-related risk |
Cumulative injection burden |
The FDA first approved SUSVIMO in October 2021 for adults with previously treated neovascular age-related macular degeneration who had responded to at least two prior anti-VEGF injections. The agency later expanded the label to diabetic macular edema and diabetic retinopathy in 2022. [1]
What is the FDA and regulatory status of SUSVIMO?
SUSVIMO is an FDA-approved biologic-device combination product. Its regulatory status is based on ranibizumab, a recombinant humanized monoclonal antibody fragment, delivered through the PDS implant.
FDA approval timeline
| Date |
Regulatory event |
| October 2021 |
FDA approval for neovascular age-related macular degeneration |
| June 2022 |
FDA approval for diabetic macular edema and diabetic retinopathy |
| October 2022 |
Roche announced a voluntary recall of SUSVIMO ocular implants in the United States |
| 2023 |
Roche reported regulatory and manufacturing actions supporting U.S. return of the product |
| 2024 |
SUSVIMO remained commercially available in the United States under revised manufacturing and quality controls |
The 2022 recall followed reports of septum dislodgement from the implant during refill procedures. The dislodged septum could enter the vitreous cavity and cause serious ocular complications. Roche suspended commercial distribution and initiated a recall while investigating the problem. [2]
The recall materially affected launch momentum. It interrupted physician training, reduced procedural confidence, and gave competing injection-based products more time to secure treatment share.
What caused the SUSVIMO recall and how did it affect market adoption?
The central product risk was the refill procedure and the implant’s septum. The Port Delivery System requires a needle to penetrate the implant’s septum during refill. Roche identified cases in which the septum could dislodge from the implant. The company attributed the issue to a manufacturing defect and implemented corrective actions before resuming distribution. [2]
The commercial effects were significant:
- Patients and physicians faced uncertainty about ongoing access.
- Retina specialists had to reconsider surgical implantation for new patients.
- Competing products retained patients on familiar injection schedules.
- Roche’s field force had to rebuild confidence in the device and refill process.
- Payers and provider organizations had less reason to change established treatment protocols.
SUSVIMO’s clinical efficacy remained based on ranibizumab exposure and the PDS delivery system. The recall therefore affected product reliability and execution risk rather than eliminating the underlying clinical rationale.
How does SUSVIMO compare with VABYSMO, EYLEA HD, and Lucentis?
SUSVIMO competes in a market where treatment durability is improving without requiring an implanted device. That shift has weakened its differentiation.
| Product |
Company |
Active ingredient |
Delivery |
Key durability proposition |
Commercial position |
| SUSVIMO |
Roche/Genentech |
Ranibizumab |
Port Delivery System implant |
Approximately six-month refill interval |
Niche device-based option |
| VABYSMO |
Roche/Genentech |
Faricimab |
Intravitreal injection |
Up to four-month dosing in selected patients |
Roche’s major retinal growth product |
| EYLEA HD |
Regeneron/Bayer |
High-dose aflibercept |
Intravitreal injection |
Up to four-month dosing in selected patients |
Direct durability competitor |
| EYLEA |
Regeneron/Bayer |
Aflibercept |
Intravitreal injection |
Commonly eight-week or longer dosing |
Large installed base |
| Lucentis |
Roche/Genentech |
Ranibizumab |
Intravitreal injection |
Shorter dosing intervals |
Mature and declining product |
| Beovu |
Novartis |
Brolucizumab |
Intravitreal injection |
Extended dosing in some patients |
Safety concerns limit use |
| Cimerli and Byooviz |
Biogen and Samsung Bioepis |
Ranibizumab biosimilars |
Intravitreal injection |
Similar molecule to Lucentis |
Price competition |
VABYSMO is the most important internal competitor. It provides an extended-dosing option without surgery and has a broader physician adoption pathway. Roche reported strong VABYSMO growth after its 2022 launch, driven by wet AMD and diabetic macular edema. [3]
EYLEA HD, approved by the FDA in August 2023, increases pressure on SUSVIMO by offering higher-dose aflibercept with longer intervals while preserving the standard injection workflow. [4]
SUSVIMO can still be differentiated for patients who are well suited to a six-month refill model and for practices that have developed implant and refill expertise. Its addressable market is narrower than the total anti-VEGF market because not every patient is an appropriate surgical candidate.
What is the financial trajectory of SUSVIMO?
Roche does not report a consistent standalone annual revenue series for SUSVIMO. Its public financial disclosures emphasize larger products, including VABYSMO, OCREVUS, Hemlibra, Tecentriq, and Perjeta. SUSVIMO has not been identified by Roche as a major group revenue contributor.
The financial trajectory is best characterized as launch, interruption, controlled re-entry, and limited scale:
| Period |
Financial and commercial development |
| 2021 |
Initial U.S. launch after FDA approval; revenue contribution began from a small installed base |
| 2022 |
Label expansion increased theoretical market size, but the recall disrupted sales and physician uptake |
| 2023 |
Reintroduction supported by manufacturing changes; commercial recovery remained gradual |
| 2024 |
Product remained strategically relevant but financially subordinate to VABYSMO and established injection products |
Roche’s retinal franchise growth has increasingly come from VABYSMO rather than SUSVIMO. Roche reported VABYSMO sales of approximately CHF 2.4 billion in 2023, compared with a much smaller and less separately disclosed contribution from SUSVIMO. [3]
The key financial issue is not the size of the anti-VEGF market. That market is large and recurring. The issue is whether SUSVIMO can capture enough share to offset:
- Implant surgery and operating-room or procedure-room costs
- Physician training and credentialing
- Refill infrastructure
- Patient selection constraints
- Recall-related reputational damage
- Competition from longer-acting injectable products
- Potential reimbursement friction for the device procedure
A successful SUSVIMO model would generate recurring revenue from the initial implant, refill doses, replacement procedures, and continued physician utilization. The model becomes less attractive if patients discontinue, the implant requires surgical management, or physicians prefer injectable products with comparable dosing intervals.
What patents and exclusivity protect SUSVIMO?
SUSVIMO is protected through a combination of biologic exclusivity, ranibizumab-related intellectual property, device patents, formulation patents, manufacturing know-how, and method-of-use claims. Because SUSVIMO is a biologic-device combination, its protection is not represented by a simple Orange Book patent list.
Orange Book and Purple Book status
The FDA Orange Book primarily covers approved small-molecule drugs and certain drug products. Biologic products are generally associated with the FDA Purple Book and the Biologics Price Competition and Innovation Act framework. SUSVIMO’s patent position must therefore be analyzed across:
- The ranibizumab biologic
- The PDS implant
- The refill needle and refill process
- Drug formulation and concentration
- Manufacturing and filling processes
- Implant placement and maintenance methods
- Indication-specific treatment methods
A biosimilar applicant would face the 351(k) pathway rather than a conventional Abbreviated New Drug Application with a standard Paragraph IV certification.
Paragraph IV challenges and biosimilar risk
No conventional Paragraph IV pathway applies to SUSVIMO as a biologic product. A biosimilar competitor could seek FDA approval for ranibizumab, but an interchangeable ranibizumab injection would not automatically reproduce the PDS implant, refill system, surgical workflow, or device-related intellectual property.
The main competitive risks are therefore separate:
- Ranibizumab biosimilars can pressure Lucentis and may reduce the perceived value of branded ranibizumab.
- A biosimilar or follow-on product using a competing sustained-delivery device could challenge SUSVIMO directly.
- Competing long-acting biologics can erode the commercial need for an implant without infringing SUSVIMO’s device claims.
- Device patents and manufacturing know-how may create greater practical barriers than molecule exclusivity.
The most relevant biosimilar products in the ranibizumab market include Byooviz and Cimerli. Their approval and commercialization increase price pressure around injectable ranibizumab, but they do not establish automatic substitutability with SUSVIMO. [5]
What patent litigation or settlement agreements affect SUSVIMO?
Publicly identified patent disputes involving SUSVIMO have not produced a major generic-entry event comparable to Paragraph IV litigation for small-molecule drugs. The most important legal risk is potential future device or combination-product litigation involving:
- Competing ocular implants
- Refill mechanisms
- Sustained-release delivery systems
- Ranibizumab formulations
- Manufacturing processes
- Biosimilar or follow-on biologic products
The 2022 recall was a product-quality and regulatory event, not a patent loss. It did not invalidate Roche’s intellectual property or create an immediate legal right for a competitor to market an equivalent PDS product.
The practical strength of the estate is therefore mixed. Roche has meaningful know-how and device protection, but the commercial moat is less secure than a broad composition-of-matter patent around a new molecule. Competitors can attack the market through alternative delivery systems or longer-acting injectable antibodies without copying the PDS architecture.
When does SUSVIMO lose exclusivity?
SUSVIMO does not have a single publicly determinative loss-of-exclusivity date comparable to a small-molecule product with one principal patent.
Key exclusivity considerations include:
- The underlying ranibizumab biologic exclusivity period
- Patent terms covering the PDS implant
- Patents covering refill procedures and formulations
- Pediatric exclusivity, if applicable
- Regulatory exclusivity for the approved biologic
- Separate patent terms for device and manufacturing claims
The first FDA approval occurred in 2021, so the statutory reference point for the biologic’s 12-year reference-product exclusivity period under the U.S. BPCIA framework would extend into the early 2030s. That period does not by itself block every competing product, particularly products using different molecules or delivery systems. Device and formulation patents could extend practical market protection beyond the initial biologic exclusivity period.
What generic launch scenarios exist for SUSVIMO?
The most plausible market-entry scenarios are:
Scenario 1: Injectable ranibizumab erosion
Ranibizumab biosimilars continue to reduce Lucentis pricing and may make physicians less willing to use a premium branded ranibizumab delivery system. This scenario pressures SUSVIMO indirectly.
Scenario 2: Competing long-acting injections
VABYSMO, EYLEA HD, and future extended-duration anti-VEGF products meet the durability need without implantation. This is the most immediate competitive threat.
Scenario 3: Direct sustained-delivery competition
A rival company develops an ocular implant, depot, or gene-therapy approach that provides six-month or longer treatment intervals. This would challenge SUSVIMO’s core value proposition.
Scenario 4: Limited direct substitution
SUSVIMO remains a specialized option for patients with high injection burden, reliable follow-up, and suitability for ocular surgery. Under this scenario, Roche maintains a modest recurring franchise without achieving mass-market penetration.
The fourth scenario is the most consistent with the product’s current commercial profile.
How strong is the SUSVIMO commercial and patent estate?
SUSVIMO’s estate is stronger in device engineering, clinical development, manufacturing controls, and physician know-how than in molecule-level exclusivity. Its commercial strength is constrained by the need for an invasive procedure.
| Factor |
Assessment |
| Clinical differentiation |
Moderate, based on reduced administration frequency |
| Device differentiation |
High relative to standard injections |
| Physician adoption |
Limited by surgery and refill training |
| Regulatory status |
Strong, with three approved retinal indications |
| Revenue scale |
Small relative to VABYSMO and EYLEA |
| Biosimilar exposure |
Indirect for the device, direct for ranibizumab injection economics |
| Recall risk |
Material historical overhang |
| Patent durability |
Potentially meaningful but dependent on device and formulation claims |
| Near-term growth |
Constrained |
| Long-term upside |
Dependent on procedure adoption and competitive durability |
What is the investment and licensing outlook for SUSVIMO?
For Roche, SUSVIMO is strategically useful because it protects a delivery platform and provides a differentiated retinal option. It is unlikely to be the primary growth engine of the ophthalmology franchise while VABYSMO is expanding rapidly.
For licensing or partnership analysis, the most valuable assets are the PDS platform, implant manufacturing capability, refill technology, and clinical infrastructure. A transaction involving SUSVIMO would need to account for the operational burden of training surgeons and maintaining product-quality controls.
Revenue upside depends on conversion from high-frequency injection patients. The product has less value in patients already controlled on four-month injectable regimens. Its strongest target population consists of patients with persistent treatment burden, reliable clinic attendance, and an acceptable surgical risk profile.
Key Takeaways
- SUSVIMO is Roche’s ranibizumab implant product using the Port Delivery System.
- FDA-approved indications include neovascular AMD, diabetic macular edema, and diabetic retinopathy.
- The product’s principal benefit is approximately six-month refill-based treatment rather than repeated injections.
- A 2022 recall involving septum dislodgement disrupted launch momentum and physician adoption.
- VABYSMO is Roche’s main retinal growth product and is a major internal competitor.
- EYLEA HD provides a direct durability alternative without requiring ocular implantation.
- Roche does not publicly report a reliable standalone SUSVIMO revenue series.
- SUSVIMO is not a conventional Orange Book product, and Paragraph IV litigation is not the relevant generic-entry framework.
- Ranibizumab biosimilars affect the economics of injectable ranibizumab but do not automatically substitute for the PDS implant.
- The product’s long-term value depends on device reliability, refill adoption, procedure reimbursement, and the pace of competing long-acting therapies.
FAQs About SUSVIMO Market and Exclusivity
Is SUSVIMO a biosimilar of Lucentis?
No. SUSVIMO contains ranibizumab, the same active ingredient used in Lucentis, but it is delivered through the Port Delivery System implant rather than by standard intravitreal injection.
Can Cimerli or Byooviz be substituted for SUSVIMO?
No automatic substitution exists. Cimerli and Byooviz are injectable ranibizumab biosimilars and do not replicate the SUSVIMO implant or refill procedure.
Is SUSVIMO listed in the FDA Orange Book?
SUSVIMO is a biologic-device combination product, so the Orange Book is not the primary reference for its regulatory exclusivity. Biologic and biosimilar issues are generally evaluated under the Purple Book and BPCIA framework.
What is the main commercial risk to SUSVIMO?
The main risk is competition from long-acting injectable products, especially VABYSMO and EYLEA HD, which can reduce injection frequency without requiring implant surgery.
Does the SUSVIMO recall mean the product was withdrawn permanently?
No. Roche recalled the product in 2022 and later pursued corrective actions and commercial reintroduction. The recall disrupted adoption but did not permanently eliminate SUSVIMO from the U.S. market.
References
-
U.S. Food and Drug Administration. (2021). FDA approves new implantable drug delivery system for treatment of wet age-related macular degeneration. FDA.
-
Genentech. (2022). Genentech provides update on SUSVIMO ocular implant recall and manufacturing improvements. Roche/Genentech.
-
Roche Holding AG. (2024). Annual report 2023: Group results and product sales. Roche.
-
U.S. Food and Drug Administration. (2023). FDA approves EYLEA HD for wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. FDA.
-
U.S. Food and Drug Administration. (2021-2022). Purple Book: Lists of licensed biological products with reference product exclusivity and biosimilar or interchangeable evaluations. FDA.
